Key Findings
In a study of 12 adults with type 1 diabetes, a single infusion of zimislecel resulted in all participants achieving an HbA1c reduction to less than 7% at one year. Notably, no severe hypoglycemia occurred during the trial period. Exogenous insulin use decreased for all participants, with 83% of the group no longer requiring exogenous insulin entirely.
Technical Details
The researchers evaluated patient-reported outcomes using the 17-item Diabetes Distress Scale and the Hypoglycemic Fear Survey-II at baseline, 90 days, 180 days, and one year. Results showed a steady decline in distress and fear scores:
- Diabetes Distress Scale: Mean scores dropped from a baseline of 3 (out of 6) to 1 point lower at 90 days, 1.3 points lower at 180 days, and 1.5 points lower at one year.
- Hypoglycemic Fear Survey-II: Mean scores dropped from a baseline of 80 (out of 132) by 25.2 points at 90 days, 34.4 points at 180 days, and 52.3 points at one year.
- Time in Range (70–180 mg/dL): Increased from 49.5% at baseline to 76.1% at 90 days, 88.3% at 180 days, and 93.3% at one year.
Background & Context
Zimislecel is an insulin-producing islet cell therapy designed to restore pancreatic islet cell function for glucose regulation. The data presented at the Breakthrough T1D Clinical and Research Congress stems from the FORWARD-VX-880-101 trial. All participants in this specific analysis had impaired hypoglycemia awareness and had experienced at least two severe hypoglycemia events in the year prior to enrollment.
Significance & Outlook
The findings suggest that stem cell-derived islet transplantation can improve quality of life beyond biochemical markers by alleviating the psychological stress of insulin-based management. While most adverse events were mild to moderate (diarrhea, headache, and nausea) and linked to immunosuppressive therapy, the need for chronic immunosuppression remains a point for future research. Michael R. Rickels noted that reducing the burden of immunosuppression agents could further improve outcomes for recipients.
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime
